Press Releases

• Sep 22, 2016 AntriaBio Announces Formation of Subsidiary and Plan to Raise Capital in South Korea
• Jun 29, 2016 AntriaBio Announces $12 Million Private Placement
• Jun 22, 2016 AntriaBio Announces Preclinical Proof of Concept for Once-Weekly Basal Insulin AB101 in Diabetic Miniature Swine
• Jan 6, 2016 AntriaBio Announces Appointment of Michael Deperro as Vice President of Operations
• Dec 10, 2015 AntriaBio Announces First Close of Private Placement Transaction
• Nov 17, 2015 AntriaBio Receives Notice of Allowance on Patent Covering Microsphere Drug Delivery Platform
• Sep 16, 2015 AntriaBio Announces New Product Candidate, AB301, a Weekly GLP-1 Agonist and Basal Insulin Combination, for Type 2 Diabetes
• Jun 29, 2015 AntriaBio Appoints David F. Welch, Ph.D. to Its Board of Directors
• Jun 8, 2015 AntriaBio Announces Promising Preclinical Results for Once-Weekly Basal Insulin AB101
• May 11, 2015 AntriaBio to Present New Preclinical Data at the American Diabetes Association 75th Scientific Sessions